Generative AI Outperforms Traditions Machine Learning in Lung Cancer Detection
Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS), reshared a post by Exai Bio on LinkedIn:
“Kudos Exai Bio!
Lung cancer is still the no.1 cause of cancer death in the USA— early detection can and must play a role in improving outcomes and saving lives.
Can’t wait to see where the technology goes from here!”
Quoting Exai Bio‘s post:
“New Publication Alert in Nature Communications.
Our latest publication features our novel generative AI platform, showcasing superior performance in detecting lung cancer compared to traditional machine learning methods. Generative AI combined with unique RNA biomarkers will play a central role in liquid biopsy and delivering on the promise of early cancer detection.
Click here to read the full publication here.”
Authors: Mehran Karimzadeh, et al.
Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.
For more Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023